Hsbc Holdings PLC Invests $9.45 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Hsbc Holdings PLC acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 151,046 shares of the biotechnology company’s stock, valued at approximately $9,451,000.

Other large investors have also modified their holdings of the company. Tsfg LLC purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at $25,000. iSAM Funds UK Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth $29,000. First Horizon Corp purchased a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at about $32,000. WPG Advisers LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 384.8% in the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 431 shares in the last quarter. Finally, Hantz Financial Services Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 177.1% during the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 471 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insider Activity

In related news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the sale, the director directly owned 52,012 shares in the company, valued at $3,998,682.56. The trade was a 5.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ARWR shares. Leerink Partners increased their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a report on Wednesday, June 17th. Chardan Capital increased their target price on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday. Sanford C. Bernstein raised their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Wall Street Zen upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, JPMorgan Chase & Co. upped their price objective on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $90.83.

Key Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported positive topline Phase 3 results for plozasiran in severe hypertriglyceridemia, supporting a potential regulatory submission later this year and strengthening the drug’s commercial outlook. Article: Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
• Positive Sentiment: Chardan Capital raised its price target on Arrowhead Pharmaceuticals from $90 to $115 and reiterated a buy rating, signaling increased analyst confidence after the trial data. Article: Read More
• Positive Sentiment: Market commentary highlights Arrowhead’s plozasiran data as a potential breakthrough that could help the company gain share in the lipid-disorder market and challenge Ionis, which adds to bullish sentiment. Article: Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug
• Neutral Sentiment: The company also announced an upcoming webcast for fiscal Q3 2026 results on August 4, which is routine investor communication and not a major immediate catalyst. Article: Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
• Neutral Sentiment: One note said the stock may look expensive after a large run, but that is more of a valuation check than a direct negative catalyst. Article: Arrowhead Pharmaceuticals (ARWR) Stock Looks Fairly Priced With Strong Sales But A Demanding 398% Run

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $88.70 on Thursday. The stock has a market cap of $12.49 billion, a P/E ratio of -41.26 and a beta of 1.26. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. The stock’s 50 day simple moving average is $77.62 and its 200 day simple moving average is $69.73. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $15.01 and a 1-year high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.17. The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.Arrowhead Pharmaceuticals’s revenue was down 86.4% on a year-over-year basis. During the same period in the previous year, the firm posted $2.75 earnings per share. As a group, equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.09 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.